Context Chronic pain in patients with advanced cancer poses a serious clinical challenge.
The Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (US Adopted …

Abstract Context Prior Phase 2/3 studies found that cannabinoids might provide adjunctive
analgesia in advanced cancer patients with uncontrolled pain. Objectives To assess …

Background: Opioids are critical for managing cancer pain, but may provide inadequate
relief and/or unacceptable side effects in some cases. Objective: To assess the analgesic …

OBJECTIVES: This study compared the efficacy of a tetrahydrocannabinol: cannabidiol
(THC: CBD) extract, a nonopioid analgesic endocannabinoid system modulator, and a THC …

Insufficient management of cancer-associated chronic and neuropathic pain adversely
affects patient quality of life. Patients who do not respond well to opioid analgesics, or have …

Background The importance of medical cannabis and cannabis-based medicines for cancer
pain management needs to be determined. Methods A systematic literature search until …

Purpose The aim of this review was to assess the efficacy of cannabis preparations for
relieving pain in patients with malignant diseases, through a systematic review of …

Context With many medications available for the management of breakthrough cancer pain
(BTCP), physicians may require additional guidance in selecting an appropriate medication …

Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a
clinical challenge. Nabiximols (Nabiximols is the US Adopted Name [USAN] for Sativex [GW …

Objective: To evaluate effectiveness, tolerability and safety of an oromucosal spray
containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as add-on treatment in …